menu search

GRPH / Down -39.59% in 4 Weeks, Here's Why Graphite Bio, Inc. (GRPH) Looks Ripe for a Turnaround

Down -39.59% in 4 Weeks, Here's Why Graphite Bio, Inc. (GRPH) Looks Ripe for a Turnaround
Graphite Bio, Inc. (GRPH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. Read More
Posted: Jan 10 2023, 11:17
Author Name: Zacks Investment Research
Views: 103126

GRPH News  

Down -39.59% in 4 Weeks, Here's Why Graphite Bio, Inc. (GRPH) Looks Ripe for a Turnaround

By Zacks Investment Research
January 10, 2023

Down -39.59% in 4 Weeks, Here's Why Graphite Bio, Inc. (GRPH) Looks Ripe for a Turnaround

Graphite Bio, Inc. (GRPH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreeme more_horizontal

Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)

By Benzinga
January 10, 2023

Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. more_horizontal

Graphite Bio: Underfollowed Gene Editing Play At An Attractive Valuation

By Seeking Alpha
December 9, 2022

Graphite Bio: Underfollowed Gene Editing Play At An Attractive Valuation

Graphite Bio has lost roughly 60% of its value over the past twelve months and is trading with a negative enterprise value despite its prospects in ge more_horizontal


Search within

Pages Search Results: